ReviewNature reviews. Cardiology2009
Vascular dysfunction in idiopathic dilated cardiomyopathy.
Review in Nature reviews. Cardiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 98 citations in OpenAlex.
- Effects of Transendocardial CD34Stem cells translational medicine · 2017Trial
- G protein regulation by RGS proteins in the pathophysiology of dilated cardiomyopathy.American journal of physiology. Heart and circulatory physiology · 2025Review
- Integrating Prime Editing and Cellular Reprogramming as Novel Strategies for Genetic Cardiac Disease Modeling and Treatment.Current cardiology reports · 2024Review
- Association between coronary microvascular dysfunction and exercise capacity in dilated cardiomyopathy.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2024Article
- Insulin-like growth factor binding protein 2: a core biomarker of left ventricular dysfunction in dilated cardiomyopathy.Hereditas · 2023Article
- Lamin A/C Ablation Restricted to Vascular Smooth Muscle Cells, Cardiomyocytes, and Cardiac Fibroblasts Causes Cardiac and Vascular Dysfunction.International journal of molecular sciences · 2023Article
- From bedside to the bench: patient-specific hiPSC-EC models uncover endothelial dysfunction in genetic cardiomyopathies.Frontiers in physiology · 2023Review
- Precision therapy in dilated cardiomyopathy: Pipedream or paradigm shift?Cambridge prisms. Precision medicine · 2023Review
- The predictive value of coronary microvascular dysfunction for left ventricular reverse remodelling in dilated cardiomyopathy.Frontiers in cardiovascular medicine · 2023Article
- Identification of Biomarkers Associated with Heart Failure Caused by Idiopathic Dilated Cardiomyopathy Using WGCNA and Machine Learning Algorithms.International journal of genomics · 2023Article
- A Comprehensive Review of Dilated Cardiomyopathy in Pre-clinical Animal Models in Addition to Herbal Treatment Options and Multi-modality Imaging Strategies.Cardiovascular & hematological disorders drug targets · 2023Review
- Contemporary Challenges of Regenerative Therapy in Patients with Ischemic and Non-Ischemic Heart Failure.Journal of cardiovascular development and disease · 2022Review
- Metabolite Signature in the Carriers of Pathogenic Genetic Variants for Cardiomyopathy: A Population-Based METSIM Study.Metabolites · 2022Article
- Cell Therapy in Heart Failure with Preserved Ejection Fraction.Cardiac failure review · 2022Review
- Elevated α-hydroxybutyrate dehydrogenase is associated with in-hospital mortality in non-ischemic dilated cardiomyopathy.Frontiers in cardiovascular medicine · 2022Article
- 3D models of dilated cardiomyopathy: Shaping the chemical, physical and topographical properties of biomaterials to mimic the cardiac extracellular matrix.Bioactive materials · 2022Review
- Stem Cell Therapy for Chronic and Advanced Heart Failure.Current heart failure reports · 2020Review
- Clinical trial in a dish using iPSCs shows lovastatin improves endothelial dysfunction and cellular cross-talk in LMNA cardiomyopathy.Science translational medicine · 2020Article
- BNP as a New Biomarker of Cardiac Thyroid Hormone Function.Frontiers in physiology · 2020Article
- Myocardial ischemia and coronary disease in heart failure.Heart failure reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic dilated cardiomyopathy (IDCM) is defined as myocardial dilatation and dysfunction in the absence of overt coronary heart disease. Myocardial injury and genetic or environmental factors can lead to the development of IDCM, which was historically characterized by marked abnormalities in the function and integrity of cardiomyocytes. However, cardiac endothelial dysfunction has also been shown to be associated with progression and poor prognosis of IDCM. Moreover, marked vascular derangements and impaired vasculogenic and angiogenic responses have been reported in patients with IDCM. On the basis of these data we re-examine IDCM pathophysiology as a downstream complication of vascular derangements that contribute to myocyte damage. Animal models closely resembling the marked vascular alterations found in patients with IDCM will be of paramount importance for further enhancing our comprehension of disease progression and for testing new drugs and stem-cell or gene-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.